SAN DIEGO, May 18, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the receipt of a $2.5 million cash payment from AnGes MG, Inc., related to continued progress in the company’s ongoing Allovectin-7(r) Phase 3 metastatic melanoma trial. Through a series of cash payments and equity investments under a previously announced collaborative agreement, Vical has received $20.1 million to date of the $22.6 million total committed by AnGes. The trial is expected to complete enrollment of the planned 375 subjects by year-end 2009.
